Market open
Voyager Therapeutics/$VYGR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Voyager Therapeutics
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Ticker
$VYGR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
162
Website
VYGR Metrics
BasicAdvanced
$387M
Market cap
39.93
P/E ratio
$0.18
EPS
0.96
Beta
-
Dividend rate
Price and volume
Market cap
$387M
Beta
0.96
52-week high
$11.72
52-week low
$5.71
Average daily volume
655K
Financial strength
Current ratio
9.508
Quick ratio
9.326
Long term debt to equity
11.987
Total debt to equity
13.995
Management effectiveness
Return on assets (TTM)
-1.11%
Return on equity (TTM)
3.38%
Valuation
Price to earnings (TTM)
39.926
Price to revenue (TTM)
2.503
Price to book
1.15
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-16.158
Growth
Revenue change (TTM)
-26.22%
Earnings per share change (TTM)
-92.38%
3-year revenue growth (CAGR)
2.83%
3-year earnings per share growth (CAGR)
-27.75%
What the Analysts think about VYGR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Voyager Therapeutics stock.
VYGR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VYGR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VYGR News
AllArticlesVideos
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
GlobeNewsWire·2 days ago
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
GlobeNewsWire·3 days ago
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Voyager Therapeutics stock?
Voyager Therapeutics (VYGR) has a market cap of $387M as of November 08, 2024.
What is the P/E ratio for Voyager Therapeutics stock?
The price to earnings (P/E) ratio for Voyager Therapeutics (VYGR) stock is 39.93 as of November 08, 2024.
Does Voyager Therapeutics stock pay dividends?
No, Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Voyager Therapeutics dividend payment date?
Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders.
What is the beta indicator for Voyager Therapeutics?
Voyager Therapeutics (VYGR) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.